TY - JOUR
T1 - Long-acting cabotegravir and rilpivirine for HIV-1 suppression
T2 - switch to 2-monthly dosing after 5 years of daily oral therapy
AU - Mills, Anthony
AU - Richmond, Gary J.
AU - Newman, Cheryl
AU - Osiyemi, Olayemi
AU - Cade, Jerry
AU - Brinson, Cynthia
AU - de Vente, Jerome
AU - Margolis, David A.
AU - Sutton, Kenneth C.
AU - Wilches, Viviana
AU - Hatch, Sarah
AU - Roberts, Jeremy
AU - McCoig, Cynthia
AU - Garris, Cindy
AU - Vandermeulen, Kati
AU - Spreen, William R.
N1 - Funding Information:
A.M. has received research funding and consulting fees from ViiV Healthcare, Gilead, Janssen Pharmaceuticals, and Merck, and consulting fees from Shionogi & Co., Ltd. G.J.R. reports grants from Gilead, ViiV Healthcare, and TaiMed. C.N. reports consulting fees from GlaxoSmithKline and ViiV Healthcare, and research support from GlaxoSmithKline and Gilead. O.O. received consulting fees from Gilead, ViiV Healthcare, and Merck. J.C. reports grants, consulting fees, and speaker fees from Gilead, ViiV Healthcare, and Merck. C.B. has received speaker fees from ViiV Healthcare and Gilead and other from GlaxoSmithKline, Janssen Pharmaceuticals, and Sangamo, outside the submitted work.
Funding Information:
The POLAR study (NCT03639311) was funded by ViiV Healthcare and Janssen Pharmaceuticals.
Funding Information:
The authors thank everyone who has contributed to the success of the study: all study participants and their families, and the clinical investigators and their staff. Professional medical writing and editorial assistance was provided by Euan Paul at SciMentum (Nucleus Global) and funded by ViiV Healthcare.
Publisher Copyright:
Copyright © 2021 The Author(s).
PY - 2022/2/1
Y1 - 2022/2/1
N2 - Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CABþRPV long-acting administered every 2 months (Q2M) in adults living with HIV-1 who previously received daily oral CABþRPV in LATTE (NCT01641809). Design: A Phase 2b, multicenter, open-label, rollover study. Methods: LATTE participants with plasma HIV-1 RNA less than 50 copies/ml who completed at least 300 weeks on study were eligible. Participants elected to switch to either CABþRPV long-acting Q2M or daily oral dolutegravir/RPV for maintenance of virologic suppression. The primary endpoint was the proportion of participants with HIV-1 RNA greater than or equal to 50 copies/ml at Month 12 (M12) per the Food and Drug Administration Snapshot algorithm. The incidence of confirmed virologic failure (CVF, two consecutive HIV-1 RNA measurements greater than or equal to 200 copies/ml), as well as safety, laboratory, and patient-reported outcomes (HIV Treatment Satisfaction and preference questionnaires) were also assessed. Results: Of 97 participants enrolled, 90 chose to receive CABþRPV long-acting and seven chose dolutegravir/RPV. At M12, no participant had HIV-1 RNA greater than or equal to 50 copies/ml or met the CVF criterion in either treatment group. No new safety signals were identified. Total treatment satisfaction was high at Baseline and remained stable through M12 across both treatment groups. Overall, 88% (n = 77/88) of long-acting arm participants preferred CABþRPV long-acting to oral CABþRPV. Conclusion: CABþRPV long-acting maintained virologic suppression in participants who had previously received daily oral CABþRPV for at least 5 years in LATTE, with a favorable safety profile. Most participants preferred CABþRPV long-acting to their prior oral CABþRPV regimen at M12.
AB - Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CABþRPV long-acting administered every 2 months (Q2M) in adults living with HIV-1 who previously received daily oral CABþRPV in LATTE (NCT01641809). Design: A Phase 2b, multicenter, open-label, rollover study. Methods: LATTE participants with plasma HIV-1 RNA less than 50 copies/ml who completed at least 300 weeks on study were eligible. Participants elected to switch to either CABþRPV long-acting Q2M or daily oral dolutegravir/RPV for maintenance of virologic suppression. The primary endpoint was the proportion of participants with HIV-1 RNA greater than or equal to 50 copies/ml at Month 12 (M12) per the Food and Drug Administration Snapshot algorithm. The incidence of confirmed virologic failure (CVF, two consecutive HIV-1 RNA measurements greater than or equal to 200 copies/ml), as well as safety, laboratory, and patient-reported outcomes (HIV Treatment Satisfaction and preference questionnaires) were also assessed. Results: Of 97 participants enrolled, 90 chose to receive CABþRPV long-acting and seven chose dolutegravir/RPV. At M12, no participant had HIV-1 RNA greater than or equal to 50 copies/ml or met the CVF criterion in either treatment group. No new safety signals were identified. Total treatment satisfaction was high at Baseline and remained stable through M12 across both treatment groups. Overall, 88% (n = 77/88) of long-acting arm participants preferred CABþRPV long-acting to oral CABþRPV. Conclusion: CABþRPV long-acting maintained virologic suppression in participants who had previously received daily oral CABþRPV for at least 5 years in LATTE, with a favorable safety profile. Most participants preferred CABþRPV long-acting to their prior oral CABþRPV regimen at M12.
UR - http://www.scopus.com/inward/record.url?scp=85122319264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122319264&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003085
DO - 10.1097/QAD.0000000000003085
M3 - Article
C2 - 34652287
AN - SCOPUS:85122319264
SN - 0269-9370
VL - 36
SP - 195
EP - 203
JO - AIDS
JF - AIDS
IS - 2
ER -